Reports Q4 revenue $1.94B, consensus $1.93B. “We are pleased to conclude a very successful year with strong fourth quarter results driven by consistent execution, including a healthy second-half growth profile,” said Ivan Tornos, Zimmer Biomet’s president and CEO. “I’m confident in our ability to carry our 2023 momentum into 2024 and to create further value for our stakeholders. As we look ahead, we remain laser focused on our priorities to advance people and culture, achieve operational excellence and drive innovation and diversification to deliver on our Mission.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results
- Is ZBH a Buy, Before Earnings?
- Zimmer Biomet price target raised to $140 from $134 at RBC Capital
- Zimmer Biomet downgraded to In Line from Outperform at Evercore ISI
- Zimmer Biomet price target raised to $133 from $115 at Truist
